In vivo studies performed in tumor-bearing nude mice, showed that siRNA-Ch-HAD NPs effectively targeted tumor cells, resulting in reduced Bcl2 protein levels and inhibited tumor growth, indicating their potential for bladder cancer therapy [74]. The gene discussed is BCL2; the disease is neoplasm.